title: Defective lipolysis persists in hearts of rats with heymann nephritis in the absence of nephrotic plasma.
abstract: Catabolism of triglyceride-rich lipoproteins, including chylomicrons (CM), is reduced in the nephrotic syndrome. It has been suggested that hyperlipidemia per se might lead to reduced CM catabolism by saturating catabolic sites. Evidence also implicates disordered high-density lipoprotein function as reducing the activity of lipoprotein lipase (LPL), the final effector of CM lipolysis. To establish whether CM lipolysis would be abnormal in the absence of either abnormal rat lipoproteins or hyperlipidemia, we measured CM lipolysis by isolated perfused hearts of rats with passive Heymann nephritis. We found that lipolysis was significantly reduced by 30% at 30 minutes (246 +/- 40 mumol v 164 +/- 10 mumol fatty acid released/hr, P < 0.05). Uptake of fatty acids was also significantly less in nephrotic hearts than in control hearts (7.25% +/- 0.93% of dose v 3.32% +/- 0.011% of dose, P < 0.01). Total heart LPL activity was reduced by 40% in hearts of nephrotic animals (368.5 +/- 39.4 mumol v 210.6 +/- 25.9 mumol free fatty acid released/hr/g heart, P < 0.01). The heparin-releasable LPL pool is that pool bound to the vascular endothelium and represents the biologically active fraction. We perfused hearts with heparin and found that heparin-releasable LPL was reduced by an order of magnitude in hearts from nephrotic rats (173 +/- 33 mumol v 19.4 +/- 11.7 mumol free fatty acid released/hr/heart, P < 0.001). The decrease in this pool represented nearly entirely the difference in total heart LPL in the two groups.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, University of California Davis School of Medicine 95817.
authors.forename: G A
authors.initials: GA
authors.lastname: Kaysen
authors.forename: X M
authors.initials: XM
authors.lastname: Pan
authors.forename: W G
authors.initials: WG
authors.lastname: Couser
authors.forename: I
authors.initials: I
authors.lastname: Staprans
mesh_terms: D000818:Animals; D002914:Chylomicrons / Q000378:metabolism*; D005230:Fatty Acids, Nonesterified / Q000378:metabolism*; D005921:Glomerulonephritis / Q000201:enzymology / Q000378:metabolism*; D006493:Heparin; D066298:In Vitro Techniques; D008071:Lipoprotein Lipase / Q000378:metabolism*; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism*; D010477:Perfusion; D051381:Rats; D017207:Rats, Sprague-Dawley; D014280:Triglycerides / Q000378:metabolism*
chemical_list: D002914:Chylomicrons; D005230:Fatty Acids, Nonesterified; D014280:Triglycerides; D006493:Heparin; D008071:Lipoprotein Lipase